TaiRx US Inc. is committed to developing novel therapeutics and precision medicine diagnostics for Nodal, a secreted protein that is normally only expressed in the embryo but that gets re-expressed in aggressive cancer progression and causes treatment resistance.
TaiRx US Inc. is a joint venture formed between TaiRx Inc., a publicly-traded pharmaceutical company headquartered in Taipei, Taiwan, and BioHealth Innovation, a regional innovation intermediary that facilitates the development of biohealth products and companies in the BioHealth Capital Region.
TaiRx US Inc. is an independent, Delaware C-Corp that has exclusive, worldwide rights to the patent estate on Nodal established by Mary J. C. Hendrix, Ph.D., the former President of the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University’s Feinberg School of Medicine, and now President of Shepherd University, who led the research delineating the critical role Nodal plays in cancer.